Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07222332 · ClinicalTrials.gov registry record · Phase 3

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

A Phase 3 study of Diabetes Mellitus, Type 1, sponsored by Eli Lilly and Company.

Recruiting
Registry status
Phase 3
Development phase
300
Enrollment target
20
Study locations

NCT07222332 is a Phase 3 study of Diabetes Mellitus, Type 1 that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 300 participants, below the 1,264-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07222332, a Phase 3 study of Diabetes Mellitus, Type 1, is actively recruiting participants, sponsored by Eli Lilly and Company.

RECRUITING
Registry status
Phase 3
Development phase
300 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.

Conditions Studied

Diabetes Mellitus, Type 1

Interventions

  • DRUG Placebo
  • DRUG Baricitinib

Study Locations (20)

Other

  • Women's and Children's Hospital - Adelaide
  • Centre for Children's Health Research - Brisbane
  • Austin Health - Repatriation Hospital - Heidelberg West
  • Ipswich Hospital - Ipswich
  • Royal Children's Hospital - Melbourne
  • Southern Adelaide Diabetes & Endocrine Services - Oaklands Park
  • The Royal Melbourne Hospital - Parkville
  • Perth Children's Hospital - Perth
  • Sydney Children's Hospital - Randwick
  • The Children's Hospital at Westmead - Westmead
  • Université Libre de Bruxelles - Hôpital Erasme - Brussels
  • UZ Brussel - Brussels
  • Cliniques universitaires Saint-Luc - Brussels
  • Antwerp University Hospital - Edegem
  • UZ Gent - Ghent

Colorado

  • Barbara Davis Center for Childhood Diabetes - Aurora

Florida

  • Tallahassee Memorial HealthCare - Tallahassee

Pennsylvania

  • Children's Hospital of Philadelphia (CHOP) - Philadelphia

Texas

  • Driscoll Children's Hospital - Corpus Christi

Virginia

  • University of Virginia - Charlottesville

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2026-02-05
Est. Completion 2028-07
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07222332

The ClinicalTrials.gov registry entry for NCT07222332 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,264-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (76% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07222332 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT07222332 about?

NCT07222332 is a clinical study titled "A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)". The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.

What is the current status of trial NCT07222332?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2026-02-05. Estimated completion is 2028-07.

What conditions does trial NCT07222332 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.

What interventions are being tested in trial NCT07222332?

The interventions under investigation include: Placebo (DRUG), Baricitinib (DRUG).

Who is sponsoring clinical trial NCT07222332?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07222332 being conducted?

This trial has 20 study locations across Colorado, Florida, Pennsylvania, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 1

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetes Mellitus, Type 1

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.